Activity, pharmacokinetics and tissue distribution of TLC ELL-12 (liposomal antitumor ether lipid) in rats with transplantable, s.c. methylnitrosourea-induced tumors

Anti-Cancer Drugs

Volumn 14, Issue 6, 2003, Pages 481-486

  Bhamra, Rupinder ^a   Bolcsak, Lois E ^a   Ahmad, Imran ^a   Schupsky, James ^a   Roberts, Patricia ^a   Stevens, Rachel ^a   Cavanaugh, Christopher ^a   Swenson, Christine E ^a  

^a Elan Pharmaceuticals   (United States)

Author keywords

Edelfosine; Ether lipid; Pharmacokinetics; Rats; TLC ELL 12; Tumor

Indexed keywords

ANTINEOPLASTIC AGENT; CARBON 14; EDELFOSINE; ETHER LIPID; LIPOSOME; METHYLNITROSOUREA; TLC ELL 12; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG FORMULATION; FEMALE; GASTROINTESTINAL TRACT; ISOTOPE LABELING; KIDNEY; LIVER; LUNG; NONHUMAN; PRIORITY JOURNAL; RAT; SPLEEN; SUBCUTANEOUS TISSUE TUMOR; TISSUE DISTRIBUTION;

ALKYLATING AGENTS; ANIMALS; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; FEMALE; HALF-LIFE; INJECTIONS, INTRAVENOUS; LIPOSOMES; METABOLIC CLEARANCE RATE; METHYLNITROSOUREA; NEOPLASMS, EXPERIMENTAL; PHOSPHOLIPID ETHERS; RATS; TISSUE DISTRIBUTION;

EID: 0043128603     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200307000-00015     Document Type: Article

References (19)

1. Perkins W, Dause RB, Li X, Franklin JC, Cabral-Lilly DJ, Zha Y, et al. Combination of antitumor ether lipid with lipids of complementary molecular shape reduces its hemolytic activity. Biochem Biophys Acta 1997; 1327:61-68.
2. Mayhew E, Ahmad I, Bhatia S, Oause R, Filep J, Janoff AS, et al. Stability of association of 1-O-octadecyl-2-O-methyl-sn-glycero-3-phosphocholine with liposome is composition dependent. Biochem Biophys Acta 1997; 1329:139-148.
3. Peters AC, Ahmad I, Janoff AS, Pushkareva MY, Mayhew E. Growth inhibitory effects of liposome-associated 1-O-Octadecyl-2-O-methyl-sn-glycero-3-phosphocholine. Lipids 1997; 32:1045-1054.
4. Ahmad I, Filep JJ, Franklin JC, Janoff AS, Masters GR, Pattassery J, et al. Enhanced therapeutic effects of liposome-associated 1-O-octadecyl-2-O-methyl-sn-glycero-3-phosphocholine. Cancer Res. 1997; 57:1915-1921.
5. Bhamra R, Bolcsak LE, Roberts P, Stevens R, Cavanaugh C, Swenson CE. Toxicity and disposition of TLC ELL-12 (liposomal antitumor ether lipid) in Sprague-Dawley rats. Anticancer Drugs 2003; 14:183-191.
6. 3 on methylnitrosourea-induced rat mammary carcinomas. Oncology 1984; 41:109-113.
7. Houlihan WJ, Lohmeyer M, Workman P, Cheon SH. Phospholipid antitumor agents. Med Res Rev 1995; 15:157-223.
8. Berdel WE, Andreesen R, Munder PG. Synthetic alkyl-phospholipid analogs: A new class of antitumor agents. In: Kuo JF (editor): Phospholipids and Cellular Regulation II. Boca Raton, FL: CRC Press; 1986, pp. 41-73.
9. Andreesen R. Ether lipids in the therapy of cancer. Prog Biochem Pharmacol 1988; 22:118-131.
10. Daniel LW. Ether lipids in experimental cancer chemotherapy. In: Hickman JA, Tritton TR (editors): Cancer Chemotherapy, Oxford: Blackwell; 1993, pp. 146-177.
11. Munder P, Westphal O. Antitumoral and other biomedical activities of synthetic ether lysophospholipids. Chem Immunol (Basel) 1990; 49: 206-235.
12. Croft SL, Snowden D, Yardley V. The activities of four anticancer alkyllysophospholipids against Leishmania donovani, Trypanosoma cruzi and Trypanosoma brucei. J Antimicrob Chemother 1996; 38:1041-1047.
13. Jha TK, Sundar S, Thakur CP, Bachmann P, Karbwang J, Fischer C, et al. Mitelfosine, an oral agent, for the treatment of Indian visceral leishmaniasis. N Engl J Med 1999; 341:1795-1800.
14. 3. Lipids 1987; 22:967-969.
15. Lohmeyer M, Bittman R. Antitumor ether lipids and alkylphosphocholines. Drugs of the Future 1994; 19:1021-1037.
16. Hong T, Ortel T, Truax C, Walker C, Bach K, Swenson C, et al. A phase I pharmacokinetic dose-escalating trial of TLC ELL-12 in patients with refractory solid tumors. Proc Am Soc Clin Oncol 2002; 21:12b (abstr 1865).
17. Pushkareva MY, Wannberg SL, Janoff AS, Mayhew E. Increased cell-surface receptor expression on U-937 cells induced by 1-O-octadecyl-2-O-methyl-sn-glycero-3-phosphocholine. Cancer Immunol Immunother 2000; 48:569-578.
18. 3 induces cytochrome c-mediated apoptosis independently of CD95 (APO-1/Fas) signalling. Blood 1999; 94:3583-3592.
19. Magistrelli A, Villa P, Benfenati E, Modest EJ, Salmona M, Tacconi MT. Fate of 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine (ET18-OME) in malignant cells, normal cells and isolated and perfused rat liver. Drug Metab Dispos 1995; 23:113-118.